Financial Ratios

SHILPA MEDICARE LTD.

NSE : SHILPAMEDBSE : 530549ISIN CODE : INE790G01031Industry : Pharmaceuticals & DrugsHouse : Private
BSE534.558.55 (+1.63 %)
PREV CLOSE ( ) 526.00
OPEN PRICE ( ) 523.10
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 63871
TODAY'S LOW / HIGH ( )515.00 541.00
52 WK LOW / HIGH ( )228.25 558
NSE534.5510.1 (+1.93 %)
PREV CLOSE( ) 524.45
OPEN PRICE ( ) 523.75
BID PRICE (QTY) 534.55 (1450)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 514687
TODAY'S LOW / HIGH( ) 515.00 541.00
52 WK LOW / HIGH ( )228.5 557.7
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)-5.702.327.9820.6316.65
   CEPS(Rs)-0.346.3310.7224.9220.82
   DPS(Rs)0.001.101.101.101.00
   Book NAV/Share(Rs)243.96237.97200.89178.27157.19
   Tax Rate(%)15.0926.6627.8420.7921.76
Margin Ratios
   Core EBITDA Margin(%)-22.273.0911.0829.5028.16
   EBIT Margin(%)-15.1210.2437.4626.8826.55
   Pre Tax Margin(%)-23.537.7035.0926.3526.13
   PAT Margin (%)-19.985.6525.3220.8720.45
   Cash Profit Margin (%)-1.1915.4033.9925.2125.57
Performance Ratios
   ROA(%)-1.830.742.879.128.44
   ROE(%)-2.371.094.2112.3011.13
   ROCE(%)-1.611.614.6713.1312.54
   Asset Turnover(x)0.090.130.110.440.41
   Sales/Fixed Asset(x)0.320.430.311.090.96
   Working Capital/Sales(x)0.632.420.841.472.28
Efficiency Ratios
   Fixed Capital/Sales(x)3.102.303.260.921.05
   Receivable days158.13164.12315.8092.44109.91
   Inventory Days144.60204.94358.7686.7194.68
   Payable days139.04218.12479.17104.54135.30
Valuation Parameters
   PER(x)0.00171.0241.8111.8520.43
   PCE(x)-678.1862.7131.159.8116.34
   Price/Book(x)0.941.671.661.372.16
   Yield(%)0.000.280.330.450.29
   EV/Net Sales(x)9.1810.1612.682.914.32
   EV/Core EBITDA(x)92.2557.9649.689.1614.06
   EV/EBIT(x)-60.7099.2233.8510.8216.27
   EV/CE(x)0.951.601.421.281.95
   M Cap / Sales8.049.6610.592.474.18
Growth Ratio
   Net Sales Growth(%)-30.6138.86-68.1121.40-10.44
   Core EBITDA Growth(%)-60.60-4.68-74.3925.520.84
   EBIT Growth(%)-202.49-62.05-55.5622.903.94
   PAT Growth(%)-345.47-69.03-61.3023.901.88
   EPS Growth(%)-345.48-70.91-61.3023.901.88
Financial Stability Ratios
   Total Debt/Equity(x)0.140.090.400.260.15
   Current Ratio(x)2.631.911.652.522.27
   Quick Ratio(x)2.261.361.011.951.50
   Interest Cover(x)-1.804.0415.8550.0563.10
   Total Debt/Mcap(x)0.140.060.240.190.07

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.